Array BioPharma
Appearance
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Array BioPharma is a clinical stage publicly traded pharmaceutical company (NASDAQ:ARRY)[1] that is in the NASDAQ Biotechnology Index and is worth over 990 million dollars.[2]
Pipeline
As of 2016, Array BioPharma has a number of compounds in clinical development.[3]
Drug Name | Stage in Clinical Trials | Development Partner | Indication | Target |
---|---|---|---|---|
Binimetinib (MEK162) | Phase 3 | None | Cancer | MEK |
Encorafenib (LGX818) | Phase 3 | Pierre Fabre | Cancer[4][5] | BRAF |
Selumetinib | Phase 3 | AstraZeneca | Cancer | MEK |
Danoprevir | Phase 3 | Roche | Hepatitis C | NS3 |
Filanesib (ARRY-520) | Phase 2 | None | Multiple myeloma[6] | KSP |
ARRY-797 | Phase 2 | None | LMNA-related DCM | p38 |
ARRY-502 | Phase 2 | None | Asthma | CRTh2 |
Ipatasertib (GDC-0068) | Phase 2 | Genentech | Cancer | AKT |
Motolimod (VTX2337) | Phase 2 | VentiRX, Celgene | Cancer | TLR |
Varlitinib (ASLAN001) | Phase 2 | ASLAN | Cancer | Pan-HER |
LY2606368 | Phase 2 | Eli Lilly | Cancer | CHEK1 |
LOXO-101 | Phase 2 | Loxo Oncology | Cancer | Pan-TRK |
ONT-380 | Phase 2 | Oncothyreon | Breast cancer | HER2/neu |
ARRY-382 | Phase 1 | None | Cancer | CSF1R |
ARRY-614 | Phase 1 | None | Myelodysplastic syndrome (MDS) | p38/Tie2 |
GDC-0575 | Phase 1 | Genentech | Cancer | CHEK1 |
GDC-0994 | Phase 1 | Genentech | Cancer | ERK |
References
- ^ "Array BioPharma Inc. (ARRY)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
- ^ "^NBI Components NASDAQ Biotechnology Stock - Yahoo! Finance". finance.yahoo.com. Yahoo Finance. Retrieved 1 November 2016.
- ^ "Product Pipeline".
- ^ "Array, Pierre Fabre global commercialization agreement closes". www.denverpost.com. Denver Post.
- ^ "Array BioPharma closes deal with French drug company". 9News. Tegna Corporation.
- ^ Gitlin, Jonathan (2011). Multiple Myeloma: New Insights for the Healthcare Professional: 2011 Edition (2011 ed.). National Human Genome Research Institute. Retrieved 4 January 2016.